Skip to content
Catalyst

PapersPMID:30871514

Green cardamom supplementation improves serum irisin, glucose indices, and lipid profiles in overweight or obese non-alcoholic fatty liver disease patients: a double-blind randomized placebo-controlled clinical trial.

BMC complementary and alternative medicine2019The record ↗

findings
3
compound
1
endpoints
3
PMID:30871514
  1. Finding, moderate evidenceraisesHDL cholesterol
  2. Finding, moderate evidencelowersHOMA-IR
  3. Finding, moderate evidencelowersTriglycerides
Study, every finding
RCT
Dose studied, every finding
3 g/day, two 0.5 g capsules per meal with food, for 3 months
Population, every finding
overweight or obese adults (30-60 years) with non-alcoholic fatty liver disease by ultrasonography; both arms given lifestyle advice (5% weight-loss diet and moderate aerobic activity)

Study record

Design
randomised controlled trial
Species
human
Population
Overweight or obese (25 <= BMI < 35) NAFLD patients aged 30-60, NIOC central hospital, Tehran; whole green cardamom powder (Elettaria cardamomum (L.) Maton, voucher PMP-669, Samex agency India) 3 g/day as 0.5 g capsules vs toast powder placebo for 3 months, with lifestyle advice to both arms; modified-ITT analysis of 87
Participants
87
Comparator
placebo
Duration
91 days
Endpoints measured
72